The abstract is read at the publisher; the summary is JClub's.
In non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (MASH), ALG-055009 reduced MRI-PDFF liver fat by placebo-adjusted -33·2% at 0·7 mg and -31·6% at 0·9 mg by week 12.
- Why it matters: Effective, safe therapies are needed for non-cirrhotic MASH, where current options do not reliably improve liver fat and histology.
- What they did: In a 12-week randomized, double-blind, placebo-controlled phase 2a trial, 102 adults (BMI ≥25 kg/m²; presumed NASH/MASH with F1–F3 fibrosis) received once-daily oral ALG-055009 (0·3, 0·5, 0·7, or 0·9 mg) or placebo, with liver fat measured by MRI-PDFF at week 12.
- The result: Placebo-adjusted least-squares mean relative changes were -14·3% (p=0·067) for 0·3 mg, -18·5% (p=0·014) for 0·5 mg, -33·2% (p<0·0001) for 0·7 mg, and -31·6% (p=0·0001) for 0·9 mg, with gastrointestinal adverse event rates similar to placebo and no deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.